Ji Zhong-He, Zhao Qi-Di, Li Yan
Department of Surgical Oncology, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, Beijing, China.
J Surg Oncol. 2024 Nov;130(6):1190-1195. doi: 10.1002/jso.27877. Epub 2024 Nov 17.
Cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) has been recommended by Peritoneal Surface Oncology Group International (PSOGI) and several other academic organizations as the treatment of choice for selected patients with gastric cancer peritoneal metastasis (GCPM). This review updates the recent progress in CRS+HIPEC for GCPM, with particular focus on the potential curing effects of this approach for subclinical GCPM patients.
细胞减灭术（CRS）联合腹腔热灌注化疗（HIPEC）已被国际腹膜表面肿瘤学组织（PSOGI）和其他几个学术组织推荐为特定胃癌腹膜转移（GCPM）患者的首选治疗方法。本综述更新了CRS+HIPEC治疗GCPM的最新进展，特别关注该方法对亚临床GCPM患者的潜在治愈效果。
